Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects

被引：0
作者：
David W. Boulton
Charles H. Smith
L. Li
Jian Huang
Angela Tang
Frank P. LaCreta
机构：
[1] Bristol-Myers Squibb,
[2] PPD,undefined
来源：
Clinical Drug Investigation | 2011年 / 31卷
关键词：
Metformin; Saxagliptin; Tablet Core; Healthy Adult Subject; Initial Combination Therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background and Objectives: As compared with individual tablets, saxagliptin/metformin extended-release (XR) fixed-dose combination (FDC) tablets offer potential for increased patient compliance with the convenience of once-daily dosing. Two bioequivalence studies assessed the fed-state bioequivalence of saxagliptin/metformin XR 5 mg/500 mg FDC (study 1) and saxagliptin/metformin XR 5mg/1000 mg FDC (study 2) relative to the same dosage strengths of individual component tablets administered concurrently. The effect of food on saxagliptin and metformin pharmacokinetics from the saxagliptin/metformin XR 5 mg/500 mg FDC and their steady-state pharmacokinetics from the saxagliptin/metformin XR 5 mg/1000 mg were also investigated.
引用
收藏
页码：619 / 630
页数：11
相关论文
共 50 条
[31]   Fixed-Dose Combination Tablet of Repaglinide and Metformin is Bioequivalent to Concomitantly Administered Individual Tablets of Repaglinide and MetforminRandomized, Single-Blind, Three-Period Crossover Study in Healthy Subjects [J].
David Hoelscher ;
Pei-Ling Chu ;
William Lyness .
Clinical Drug Investigation, 2008, 28 :573-582
[32]   Pharmacokinetic Comparison Between a Fixed-Dose Combination of Empagliflozin L-Proline/Metformin and Empagliflozin/Metformin in Healthy Korean Subjects [J].
Lee, HyunJoon ;
Chung, Jae-Yong ;
Yu, Kyung-Sang ;
Park, Shin-Jung ;
Lee, Soyoung .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (12) :1156-1163
[33]   Fixed dose combination of dapagliflozin, glimepiride and extended-release metformin tablets in patients with type 2 diabetes poorly controlled by metformin and glimepiride: A phase III, open label, randomized clinical study in India [J].
Sahay, Rakesh ;
Gangwani, Dinesh ;
Singh, Manish ;
Gupta, Sandeep ;
Kale, Narendra ;
Srivastava, Manoj ;
Kurmi, Prakash ;
Ambaliya, Jayesh ;
Lomte, Nilesh ;
Gofne, Sandip ;
Agarwal, Saurabh ;
Kashid, Priyanka ;
Agarwal, Vikas ;
Rai, Pradeep ;
Sharma, Surendra ;
Murthy, L. Sreenivasa ;
Rajurkar, Mandodari ;
Saha, Shruti ;
Patel, Piyush ;
Patil, Dipak ;
Ghadge, Pravin ;
Lakhwani, Lalit ;
Mehta, Suyog ;
Joglekar, Sadhna J. .
DIABETES OBESITY & METABOLISM, 2025, 27 (04) :2193-2205
[34]   Efficacy of Alogliptin/Metformin Fixed-Dose Combination Tablets and Vildagliptin/Metformin Fixed-Dose Combination Tablets on Glycemic Control in Real-World Clinical Practice for the Patients with Type 2 Diabetes: A Multicenter, Open-Label, Randomized, Parallel Group, Comparative Trial [J].
Abe, Tomoe ;
Takeda, Yasutaka ;
Sakuma, Ichiro ;
Okada, Mizuho ;
Kurigaki, Ayaka ;
Bessho, Ryoichi ;
Sato, Mao ;
Kitsunai, Hiroya ;
Takiyama, Yumi ;
Sakurai, Masaru .
METABOLIC SYNDROME AND RELATED DISORDERS, 2024, 22 (09) :651-660
[35]   Population Pharmacokinetic Modeling and Noncompartmental Analysis Demonstrated Bioequivalence Between Metformin Component of Metformin/Vildagliptin Fixed-Dose Combination Products and Metformin Immediate-Release Tablet Sourced From Various Countries [J].
Chitnis, Shripad D. ;
Han, Yi ;
Yamaguchi, Masayuki ;
Mita, Sachiko ;
Zhao, Rong ;
Sunkara, Gangadhar ;
Kulmatycki, Kenneth .
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2016, 5 (01) :40-51
[36]   Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects [J].
Jin, Xuanyou ;
Kim, Eunwoo ;
Huh, Ki Young ;
Hwang, Inyoung ;
Cho, Joo-Youn ;
Yu, Kyung-Sang ;
Lee, SeungHwan .
TRANSLATIONAL AND CLINICAL PHARMACOLOGY, 2020, 28 (01) :43-54
[37]   Real-world experience of treatment individualization based on a fixed-dose combination of gliclazide extended release+ metformin extended-release in type 2 diabetes mellitus [J].
Kalra, Sanjay ;
Jagadeesha, Aravinda ;
Khandelwal, Deepak ;
Samudra, Kirti ;
Gadve, Sharvil ;
Bhattacharyya, Supratik .
CLINICAL DIABETOLOGY, 2021, 10 (04) :337-341
[38]   Dapagliflozin/Saxagliptin Fixed-Dose Tablets: A New Sodium-Glucose Cotransporter 2 and Dipeptidyl Peptidase 4 Combination for the Treatment of Type 2 Diabetes [J].
Coppenrath, Valerie Azzopardi ;
Hydery, Tasmina .
ANNALS OF PHARMACOTHERAPY, 2018, 52 (01) :78-85
[39]   Development and validation of a hydrophilic interaction liquid chromatography method for the quantitation of impurities in fixed-dose combination tablets containing rosuvastatin and metformin [J].
Machairas, George ;
Panderi, Irene ;
Geballa-Koukoula, Ariadni ;
Rozou, Stavroula ;
Antonopoulos, Nikolaos ;
Charitos, Christos ;
Vonapartia, Ariadni .
TALANTA, 2018, 183 :131-141
[40]   Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects [J].
Kim, S. ;
Jang, I-J ;
Shin, D. ;
Shin, D. S. ;
Yoon, S. ;
Lim, K. S. ;
Yu, K-S ;
Li, J. ;
Zhang, H. ;
Liu, Y. ;
Brendel, E. ;
Blode, H. ;
Wang, Y. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (04) :424-431
12345